Trial Condition(s):

Vascular Diseases

Efficacy and safety study to evaluate Gadavist (Gadobutrol) as contrast agent in Magnetic Resonance Imaging (MRI) of vascular diseases in Chinese patients

Bayer Identifier:

91537

ClinicalTrials.gov Identifier:

NCT00395733

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.

Inclusion Criteria
- Chinese origin
 - Known or suspected blood vessel diseases
Exclusion Criteria
- Pregnancy
 - Lactation
 - Conditions interfering with  MRI
 - Allergy to any contrast agent or any drugs
 - Participation in other trial
 - Require emergency treatment
 - Severely impaired liver and kidney functions

Trial Summary

Enrollment Goal
83
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Gadavist/Gadovist (Gadobutrol, BAY86-4875)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Affiliated Ruijin Hosp. Shanghai Jiaotong Univ. Med School

Shanghai, China, 200025

Status
Completed
 
Locations

Chinese PLA General Hosp.

Beijing, China, 100853

Status
Completed
 
Locations

West China Hospital, Sichuan University

Chengdu, China, 610041

Status
Completed
 

Trial Design